0.6067

5.60% 0.0322

Pre-market: .62 0.0133 +2.19%

Humacyte Inc (HUMA)

Overview News Price History Option Chain Financials Why HUMA Down? Discussions Forecast

Humacyte Inc stock is traded at $0.6067, with a volume of 7.06M. It is up +5.60% in the last 24 hours and down -45.59% over the past month. Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Previous Close:

$0.5745

Open:

$0.589

24h Volume:

7.06M

Relative Volume:

1.04

Market Cap:

$134.70M

Revenue:

$2.04M

Net Income/Loss:

$-43.21M

P/E Ratio:

-2.9352

EPS:

-0.2067

Net Cash Flow:

$-105.93M

1W Performance:

-23.63%

1M Performance:

-45.59%

6M Performance:

-65.13%

1Y Performance:

-64.42%

1-Day Range:

$0.5601

$0.6253

1-Week Range:

$0.5469

$0.90

52-Week Range:

$0.5469

$2.93

Humacyte Inc Stock (HUMA) Company Profile

Name

Humacyte Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

919-313-9633

Address

2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM

Employee

220

Twitter

Next Earnings Date

2026-03-27

Latest SEC Filings

HUMA's Discussions on Twitter

Compare HUMA vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HUMA Humacyte Inc	0.6067	134.70M	2.04M	-43.21M	-105.93M	-0.2067
VRTX Vertex Pharmaceuticals Inc	446.54	113.44B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	772.64	81.68B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	730.25	45.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.87	43.88B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.52	35.25B	606.42M	-1.28B	-997.58M	-6.403

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-27-25	Initiated	Barclays	Overweight
May-14-25	Resumed	H.C. Wainwright	Buy
Dec-20-24	Reiterated	H.C. Wainwright	Buy
Dec-11-23	Initiated	H.C. Wainwright	Buy
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight
Oct-29-21	Initiated	Cowen	Outperform
Sep-24-21	Initiated	Oppenheimer	Outperform
Sep-22-21	Initiated	BTIG Research	Buy
Sep-16-21	Initiated	Piper Sandler	Overweight

View All

Humacyte Inc Stock (HUMA) Latest News

Mar 31, 2026

HUMA: Benchmark Downgrades Humacyte with Lowered Price Target | HUMA Stock News - GuruFocus

Mar 31, 2026

Benchmark Reaffirms "Speculative Buy" Rating for Humacyte (NASDAQ:HUMA) - marketbeat.com

Mar 31, 2026

Earnings Miss: Can Humacyte Inc sustain its profitabilityPortfolio Growth Summary & Low Risk High Win Rate Picks - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Aug Macro: Does Humacyte Inc Equity Warrant have declining or rising EPS2026 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 30, 2026

Why BTIG cut its target on Humacyte (HUMA) but kept a bullish view on the bigger opportunity - MSN

Mar 30, 2026

Piper Sandler Cuts Humacyte (NASDAQ:HUMA) Price Target to $1.00 - marketbeat.com

Mar 30, 2026

Piper Sandler cuts Humacyte stock price target on weak sales By Investing.com - Investing.com Canada

Mar 30, 2026

Piper Sandler cuts Humacyte stock price target on weak sales - Investing.com

Mar 30, 2026

TD Cowen Has Lowered Expectations for Humacyte (NASDAQ:HUMA) Stock Price - marketbeat.com

Mar 30, 2026

TD Cowen lowers Humacyte stock price target to $1 on launch concerns - Investing.com Australia

Mar 30, 2026

Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Cuts Target Price to $1 - Moomoo

Mar 30, 2026

TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $1 - Moomoo

Mar 30, 2026

Mar 29, 2026